UTHR Related Major News
-
United Therapeutics (UTHR) Posts Q1 EPS of $1.24
-
United Therapeutics (UTHR) Falls after FDA Again Fails to Approve Oral Treprostinil NDA
-
United Therapeutics (UTHR) Tops Q4 EPS Views; Guides FY13 Revs
-
United Therapeutics (UTHR) Tops Q3 EPS by 26c; Reaffirms Outlook
-
United Therapeutics (UTHR) Receives CRL from FDA for Oral Treprostinil
-
United Therapeutics (UTHR) Tops Q2 EPS by 22c
-
United Therapeutics (UTHR) Tops Q1 EPS Views; Reaffirms Outlook
-
United Therapeutics Corp (UTHR) Reports Q4 EPS of $0.79, Reaffirms FY12, FY13 Guidance
-
United Therapeutics Corp (UTHR) Easily Beats Q3 Views; Revs Top $200M
-
United Therapeutics Corp (UTHR) Tops Q2 EPS Views
-
United Therapeutics Corp. (UTHR) Tops Q1 EPS Views
-
United Therapeutics Corp. (UTHR) Posts Mixed Q4 Results
-
United Therapeutics (UTHR) Posts Q3 non-GAAP EPS of $0.66, Tops Views
-
United Therapeutics (UTHR) Posts Q2 EPS of $0.67, Beats Views
-
United Therapeutics (UTHR) Posts Q1 EPS of $0.35, Beats Views by 6c
-
United Therapeutics Corp. (UTHR) Posts Q4 non-GAAP EPS of $0.62, Tops Views
-
United Therapeutics (UTHR) Tops Estimates, Posts Q3 $0.66
-
United Therapeutics (UTHR) Reports Q2 Loss of $0.09
-
United Therapeutics (UTHR) Announces FDA Approval For Pulmonary Arterial Hypertension Treatment TYVASO
-
United Therapeutics (UTHR) Reports Q1 Earnings
-
United Therapeutics (UTHR) Reports Q2 Results
-
United Therapeutics (UTHR) Misses Q3 EPS by 8c
-
United Therapeutics (UTHR) Reports Q2 EPS of $0.63, Beats by 5c
-
United Therapeutics (UTHR) Reports Q1 Results
-
United Therapeutics (UTHR) Said OvaRex MAb Trials Failed
Back to UTHR Stock Lookup
